RIC in COVID-19-a Clinical Trial to Investigate Whether Remote Ischemic Conditioning (RIC) Can Prevent Deterioration to Critical Care in Patients with COVID-19

Sean M Davidson, Kishal Lukhna, Diana A Gorog, Alan D Salama, Alejandro Rosell Castillo, Sara Giesz, Pelin Golforoush, Siavash Beikoghli Kalkhoran, Sandrine Lecour, Aqeela Imamdin, Helison R P do Carmo, Ticiane Gonçalez Bovi, Mauricio W Perroud Jr, Mpiko Ntsekhe, Andrei C Sposito, Derek M Yellon, Sean M Davidson, Kishal Lukhna, Diana A Gorog, Alan D Salama, Alejandro Rosell Castillo, Sara Giesz, Pelin Golforoush, Siavash Beikoghli Kalkhoran, Sandrine Lecour, Aqeela Imamdin, Helison R P do Carmo, Ticiane Gonçalez Bovi, Mauricio W Perroud Jr, Mpiko Ntsekhe, Andrei C Sposito, Derek M Yellon

Abstract

Purpose: Coronavirus disease 19 (COVID-19) has, to date, been diagnosed in over 130 million persons worldwide and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Several variants of concern have emerged including those in the United Kingdom, South Africa, and Brazil. SARS-CoV-2 can cause a dysregulated inflammatory response known as a cytokine storm, which can progress rapidly to acute respiratory distress syndrome (ARDS), multi-organ failure, and death. Suppressing these cytokine elevations may be key to improving outcomes. Remote ischemic conditioning (RIC) is a simple, non-invasive procedure whereby a blood pressure cuff is inflated and deflated on the upper arm for several cycles. "RIC in COVID-19" is a pilot, multi-center, randomized clinical trial, designed to ascertain whether RIC suppresses inflammatory cytokine production.

Methods: A minimum of 55 adult patients with diagnosed COVID-19, but not of critical status, will be enrolled from centers in the United Kingdom, Brazil, and South Africa. RIC will be administered daily for up to 15 days. The primary outcome is the level of inflammatory cytokines that are involved in the cytokine storm that can occur following SARS-CoV-2 infection. The secondary endpoint is the time between admission and until intensive care admission or death. The in vitro cytotoxicity of patient blood will also be assessed using primary human cardiac endothelial cells.

Conclusions: The results of this pilot study will provide initial evidence on the ability of RIC to suppress the production of inflammatory cytokines in the setting of COVID-19.

Trial registration: NCT04699227, registered January 7th, 2021.

Keywords: COVID-19; Clinical trial; Cytokines; Endothelial cells; Immunosuppression; Remote ischemic conditioning.

Conflict of interest statement

The authors declare no competing interests.

© 2021. The Author(s).

References

    1. Sorci G, Faivre B, Morand S. Explaining among-country variation in COVID-19 case fatality rate. Sci Rep. 2020;10(1):18909. doi: 10.1038/s41598-020-75848-2.
    1. Leung K, Shum MH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Euro Surveill. 2021;26(1). 10.2807/1560-7917.ES.2020.26.1.2002106.
    1. Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, et al. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies. Cell Host Microbe. 2021;29(3):463–76.e6. doi: 10.1016/j.chom.2021.02.003.
    1. Pearce L, Davidson SM, Yellon DM. The cytokine storm of COVID-19: a spotlight on prevention and protection. Expert Opin Ther Targets. 2020;24(8):723–730. doi: 10.1080/14728222.2020.1783243.
    1. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan. China JAMA Cardiol. 2020;5(7):802–810. doi: 10.1001/jamacardio.2020.0950.
    1. Bojkova D, Wagner JUG, Shumliakivska M, Aslan GS, Saleem U, Hansen A, et al. SARS-CoV-2 infects and induces cytotoxic effects in human cardiomyocytes. Cardiovasc Res. 2020;116(14):2207–2215. doi: 10.1093/cvr/cvaa267.
    1. Chung MK, Zidar DA, Bristow MR, Cameron SJ, Chan T, Harding CV, 3rd, et al. COVID-19 and cardiovascular disease: from bench to bedside. Circ Res. 2021;128(8):1214–1236. doi: 10.1161/CIRCRESAHA.121.317997.
    1. Evans PC, Rainger GE, Mason JC, Guzik TJ, Osto E, Stamataki Z, et al. Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovasc Res. 2020;116(14):2177–2184. doi: 10.1093/cvr/cvaa230.
    1. Salama C, Han J, Yau L, Reiss WG, Kramer B, Neidhart JD, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384(1):20–30. doi: 10.1056/NEJMoa2030340.
    1. Pickard JM, Botker HE, Crimi G, Davidson B, Davidson SM, Dutka D, et al. Remote ischemic conditioning: from experimental observation to clinical application: report from the 8th Biennial Hatter Cardiovascular Institute Workshop. Basic Res Cardiol. 2015;110(1):453. doi: 10.1007/s00395-014-0453-6.
    1. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. J Am Coll Cardiol. 2015;65(2):177–195. doi: 10.1016/j.jacc.2014.10.031.
    1. Honda T, He Q, Wang F, Redington AN. Acute and chronic remote ischemic conditioning attenuate septic cardiomyopathy, improve cardiac output, protect systemic organs, and improve mortality in a lipopolysaccharide-induced sepsis model. Basic Res Cardiol. 2019;114(3):15. doi: 10.1007/s00395-019-0724-3.
    1. Pearce L, Davidson SM, Yellon DM. Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response. Basic Res Cardiol. 2021;116(1):12. doi: 10.1007/s00395-021-00852-0.
    1. Hausenloy DJ, Yellon DM. The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol. 2011;8(11):619–629. doi: 10.1038/nrcardio.2011.85.
    1. Joseph B, Khalil M, Hashmi A, Hecker L, Kulvatunyou N, Tang A, et al. Survival benefits of remote ischemic conditioning in sepsis. J Surg Res. 2017;213:131–137. doi: 10.1016/j.jss.2016.01.033.
    1. Orbegozo Cortes D, Su F, Santacruz C, Hosokawa K, Donadello K, Creteur J, et al. Ischemic conditioning protects the microcirculation, preserves organ function, and prolongs survival in sepsis. Shock. 2016;45(4):419–427. doi: 10.1097/SHK.0000000000000526.
    1. Rauch A, Dupont A, Goutay J, Caplan M, Staessens S, Moussa M, et al. Endotheliopathy is induced by plasma from critically ill patients and associated with organ failure in severe COVID-19. Circulation. 2020;142(19):1881–1884. doi: 10.1161/CIRCULATIONAHA.120.050907.
    1. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377–381. doi: 10.1016/j.jbi.2008.08.010.
    1. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255–2273. doi: 10.1056/NEJMra2026131.
    1. Codo AC, Davanzo GG, Monteiro LB, de Souza GF, Muraro SP, Virgilio-da-Silva JV, et al. Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 2020;32(3):437–46.e5. doi: 10.1016/j.cmet.2020.07.007.
    1. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pillinger M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. Eur Heart J. 2021 doi: 10.1093/eurheartj/ehaa1103.
    1. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Moller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.e9. doi: 10.1016/j.cell.2020.04.026.
    1. Kiudulaite I, Belousoviene E, Vitkauskiene A, Pranskunas A. Effects of remote ischemic conditioning on microcirculatory alterations in patients with sepsis: a single-arm clinical trial. Ann Intensive Care. 2021;11(1):55. doi: 10.1186/s13613-021-00848-y.
    1. Gladka MM, Maack C. The endothelium as Achilles’ heel in COVID-19 patients. Cardiovasc Res. 2020;116(14):e195–e197. doi: 10.1093/cvr/cvaa327.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere